Original articleThe long term risk of malignancy in patients with branch duct intraductal papillary mucinous neoplasms of the pancreas
Introduction
Intraductal papillary mucinous neoplasms of the pancreas (IPMN) are premalignant lesions that might follow the lineage “dysplasia of increasing grade – invasive carcinoma”. Until 2000, the management of this disease was almost exclusively surgical irrespective of symptoms and imaging findings. Considering both the low-grade of dysplasia in the majority of surgical specimens and the morbidity and mortality of pancreatic resection, several groups decided to follow some highly selected patients without operative therapy. Preoperative risk factors of high-grade dysplasia or invasive carcinoma were therefore described allowing, as far as possible, a safe strategy of surveillance without resection [1], [2], [3], [4], [5], [6], [7]. This non-operative strategy was acknowledged by the 2006 Consensus Meeting held in Sendaï [8]. Two factors predictive of malignant transformation have been described: mural nodules and main pancreatic duct (MPD) involvement. The natural history of IPMN involving only branch ducts (BD) or MPD is markedly different with a 5-year actuarial risk of at least high-grade dysplasia being 15 and 63%, respectively [1].
Whether the risk of malignant transformation beyond 5 years is stable, increases slightly or dramatically is unknown. The aim of this study was to assess the risk of malignant evolution beyond 5 years of follow-up in BD-IPMN patients treated conservatively and carefully followed-up with a standardised prospective protocol.
Section snippets
Inclusion and exclusion criteria
All consecutive patients with BD-IPMN diagnosed and followed-up in our institution for more than 5 years between 1989 and 2010 were included. Those with signs suggesting malignant transformation at initial work-up or during the first 60 months of follow-up and those with a follow-up less than 60 months were excluded.
All patients were informed of the goals of surveillance program and gave their consent. As no therapeutic or follow-up procedures were modified by inclusion in this study, no ethic
Patients
Among our series of patients with BD-IPMN, 53 had no criteria suggestive of malignancy 60 months after diagnosis and were followed-up beyond that time in a prospective surveillance programme. Patients' characteristics are summarised in Table 1. Five patients had a follow-up >120 months. No major symptoms indicating surgery occurred in any patient.
Imaging and diagnostic findings
At the time of inclusion (that is after 60 months of follow-up), no patient had MPD involvement, development of mural nodules, or development of a
Discussion
IPMN are widely recognised as a premalignant condition leading to pancreatic adenocarcinoma. They are more and more often incidentally discovered after an abdominal imaging procedure has been performed for another condition. Until 2000, all patients with IMPN were operated on except those with general contraindication or refusal. Since that time, several groups have started to follow patients and risk factors for malignancy were progressively described. There is a consensus that MPD involvement
Conflict of interest
No conflicts of interest exist.
Author's contribution
Wafaa Khanoussi: Study design and concept, acquisition of the data, data analysis, statistical analysis and manuscript drafting.
Marie-Pierre Vullierme: Data analysis, acquisition of the data and manuscript drafting.
Vinciane Rebours: statistical analysis and manuscript drafting.
Frédérique Maire: Acquisition of the data.
Olivia Hentic: Acquisition of the data.
Frederique Maire: Acquisition of the data.
Alain Aubert: Acquisition of the data.
Alain Sauvanet: Acquisition of the data.
Safi Dokmak:
References (16)
- et al.
Natural history of intraductal papillary mucinous tumors of the pancreas: actuarial risk of malignancy
Clin Gastroenterol Hepatol
(2006) - et al.
Morphologic changes in branch duct intraductal papillary mucinous neoplasms of the pancreas: a midterm follow-up study
Clin Gastroenterol Hepatol
(2008) - et al.
Evaluation of the guidelines for management of pancreatic branch-duct intraductal papillary mucinous neoplasm
Clin Gastroenterol Hepatol
(2008) - et al.
Intraductal papillary-mucinous tumor of the pancreas concomitant with ductal carcinoma of the pancreas
Pancreatology
(2002) - et al.
Intraductal papillary mucinous neoplasms: predictors of malignant and invasive pathology
Ann Surg
(2007) - et al.
Do consensus indications for resection in branch duct intraductal papillary mucinous neoplasm predict malignancy? A study of 147 patients
Am J Gastroenterol
(2007) - et al.
Natural history of branch duct intraductal papillary-mucinous neoplasms of the pancreas without mural nodules: long-term follow-up results
Gut
(2008) - et al.
Branch-duct intraductal papillary mucinous neoplasms of the pancreas: to operate or not to operate? Results of a prospective protocol on the management of 109 consecutive patients
Gut
(2006)
Cited by (82)
Intraductal papillary mucinous neoplasms of the pancreas: Uncommon imaging presentation, evolution and comparison of guidelines
2023, European Journal of Radiology OpenPancreatic Cysts: Radiology
2023, Gastrointestinal Endoscopy Clinics of North AmericaSurveillance of Pancreatic Cystic Neoplasms
2023, Gastrointestinal Endoscopy Clinics of North AmericaInnovation in the Surgical Management of Pancreatic Cystic Neoplasms: Same Operations, Narrower Indications, and an Individualized Approach to Decision-Making
2023, Gastrointestinal Endoscopy Clinics of North AmericaBenefit of Extended Surveillance of Low-Risk Pancreatic Cysts After 5-Year Stability: A Systematic Review and Meta-Analysis
2023, Clinical Gastroenterology and Hepatology